Factors influencing serum topiramate concentrations in routine therapeutic drug monitoring in korean adult patients with epilepsy

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 177-182

  Huh, Hee Jae ^a   Joo, Eun Yeon ^a   Hong, Seung Bong ^a   Ahn, Joong Hyun ^b   Seo, Dae Won ^a   Lee, Soo Youn ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

concentrationto dose relationship; drug interaction; Korean patients; therapeutic drug monitoring; topiramate

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; KOREA; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; DRUG MONITORING; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; HUMANS; MALE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84875129535     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827efe1d     Document Type: Article

References (22)

1. Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol. 1996; 36: 884-891.
2. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002; 24: 366-374.
3. Topamax-oral tablets, oral sprinkle capsules: US Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012.
4. Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007; 67: 2231-2256.
5. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004; 43: 763-780.
6. Langtry HD, Gillis JC, Davis R. Topiramate. a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997; 54: 752-773.
7. Fröscher W, Schier KR, Hoffmann M, et al. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord. 2005; 7: 237-248.
8. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-todose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit. 2004; 26: 251-257.
9. Rosaria Muscatello M, Pacetti M, Cacciola M, et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia. 2005; 46: 771-774.
10. Christensen J, Andreasen F, Poulsen JH, et al. Randomized, concentrationcontrolled trial of topiramate in refractory focal epilepsy. Neurology. 2003; 61: 1210-1218.
11. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003; 25: 347-363.
12. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia. 2000; 41: 977-980.
13. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs?best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008; 49: 1239-1276.
14. Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol. 1999; 20: 339-344.
15. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006; 45: 351-363.
16. Dahlin MG, Ohman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol. 2004; 31: 248-253.
17. Britzi M, Perucca E, Soback S, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia. 2005; 46: 378-384.
18. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther. 1997; 19: 1294-1308.
19. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet. 2005; 44: 407-416.
20. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996; 37: 774-780.
21. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1997; 38: 324-333.
22. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia. 1997; 38(suppl 1): S18-S23.